ArticleJournal of thoracic disease2025
Increased expression of FBW7 may improve the prognosis of lung adenocarcinoma after pemetrexed chemotherapy by transforming the epithelial-to-mesenchymal process.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: FBW7 is a tumor suppressor in cancer. However, few studies have examined the role of FBW7 in lung adenocarcinoma (LUAD), especially the relationship between FBW7 and chemotherapy drug resistance in LUAD. This study analyzed the relationship between FBW7 expression and the clinicopathological features of LUAD patients, and investigated the effect of FBW7 on the efficacy of pemetrexed chemotherapy and its relationship with epithelial-to-mesenchymal transformation (EMT). Methods: A total of 101 patients admitted to Zhoushan Hospital from February 2014 to May 2018 who were pathologically diagnosed with LUAD and received pemetrexed chemotherapy were included in the study. Immunohistochemistry (IHC) was used to detect the expression of FBW7 and EMT-related target proteins in the cancer tissues of the patients, and the relationship between FBW7 and the clinicopathological features, prognosis, and EMT of the LUAD patients was analyzed. Results: FBW7 expression was high in 70 LUAD patients and low in 31 LUAD patients. The patients were followed up for 8-112 months. The 5-year progression-free survival (PFS) and overall survival (OS) were significantly higher in the high FBW7 expression group than the low FBW7 expression group (P<0.001). The Cox regression analysis showed that the higher serum carcinoembryonic antigen (CEA) [hazard ratio (HR) =2.818, 95% confidence interval (CI): 1.100-7.223, P=0.03], higher cytokeratin 19 fragment (Cyfra21-1) (HR =3.587, 95% CI: 1.168-11.015, P=0.03), radical surgery (HR =0.044, 95% CI: 0.006-0.307, P=0.002), and FBW7 expression level (HR =6.270, 95% CI: 2.106-18.660, P=0.001) were independent predictors of OS in patients with LUAD receiving pemetrexed chemotherapy. The Spearman correlation analysis showed that the expression of FBW7 was positively correlated with the expression of E-cadherin (r Conclusions: In patients with LUAD receiving pemetrexed chemotherapy, the high FBW7 expression group had a better prognosis than the low FBW7 expression group. Thus, high expression of FBW7 may affect the efficacy of pemetrexed in patients with LUAD through EMT. Our findings may provide new treatment ideas for patients with LUAD who are resistant to pemetrexed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.